by Heart Failure Association of the ESC
The HFA Cardio Talk provides the opportunity to anyone interested in Heart Failure to receive updates in the field with very specific and diverse topics, go on a deeper subject of an HFA course and to listen to a discussion of key opinion leaders with junior HF specialists. Each month, a new episode lasting approximately 15 minutes and taking the form of a conversation between a member of the HFA Young community and an internationally renowned expert is released. You can also be interested in other ESC podcasts: ESC Cardio Talk, EHRA Cardio Talk and ESC TV Today. Check them out!
Language
🇺🇲
Publishing Since
1/27/2022
Email Addresses
1 available
Phone Numbers
0 available
April 23, 2025
<p class="p1">With Justyna Sokolska, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw - Poland, and Maja Cikes, University of Zagreb School of Medicine, Head at the Unit for Heart Failure and Mechanical Circulatory Support, Department of Cardiovascular Diseases, University Hospital Center, Zagreb - Croatia.</p> <p class="p1">In this episode of HFA CardioTalk, Justyna Sokolska interviews Maja Cikes on the challenges in management of long-term left ventricular assist device in patients with advanced heart failure. The discussion emphasizes the importance of selecting appropriate patients at the optimal time, examines the adverse events and highlights major ongoing clinical trials. </p> <p class="p1">Recommended readings: </p> <p class="p1"><span class="s1"><a href= "https://pubmed.ncbi.nlm.nih.gov/37950897/">Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial</a></span>, Mehra MR, et al. JAMA. 2023 Dec 12;330(22):2171-81 </p> <p class="p1"><span class="s1"><a href= "https://pubmed.ncbi.nlm.nih.gov/35300822/">Trends and Outcomes of Left Ventricular Assist Device Therapy: JACC Focus Seminar</a></span>, Varshney AS, et al. J Am Coll Cardiol 2022 Mar 22;79(11):1092-1107</p> <p class="p1"><span class="s1"><a href= "https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1568">Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry</a></span>, Cikes M, et al. Eur J Heart Fail 2019 Sep;21(9):1129-41</p> <p class="p1"><span class="s1"><a href= "https://pubmed.ncbi.nlm.nih.gov/30883052/">A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report</a></span>, Mehra MR, et al. N Engl J Med 2019 Apr 25;380(17):1618-27</p> <p class="p1">This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.</p>
March 26, 2025
<p>With Robert M.A. van der Boon, Erasmus Medical Center, Rotterdam - The Netherlands, and Anuradha Lala, Mount Sinai Fuster Heart Hospital, New York City - USA.</p> <p class="p1">In this episode of HFA Cardio talk, we dive into how factors like sex, socio-economics status and ethnicity shape the way heart failure presents and progresses in different populations. We’ll discuss why recognizing these differences is critical for accurate diagnosis and effective treatment and highlight practical steps clinicians can take to close the gaps in prevention and care.</p> <p class="p1">Papers:</p> <p class="p1"><span class="s1"><a href= "https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2534">https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2534</a></span></p> <p class="p1"><span class="s1"><a href= "https://academic.oup.com/eurheartj/article/40/47/3859/5652224?login=true"> https://academic.oup.com/eurheartj/article/40/47/3859/5652224?login=true</a></span></p> <p class="p1"><span class="s1"><a href= "https://www.sciencedirect.com/science/article/pii/S1071916421004322?via%3Dihub"> https://www.sciencedirect.com/science/article/pii/S1071916421004322?via%3Dihub</a></span></p> <p class="p1"><span class="s1"><a href= "https://www.sciencedirect.com/science/article/pii/S0002914922010074?via%3Dihub"> https://www.sciencedirect.com/science/article/pii/S0002914922010074?via%3Dihub</a></span></p> <p class="p1"><span class="s1"><a href= "https://www.sciencedirect.com/science/article/pii/S2468266719301082?via%3Dihub"> https://www.sciencedirect.com/science/article/pii/S2468266719301082?via%3Dihub</a></span></p> <p class="p1"><span class="s1"><a href= "https://journals.lww.com/co-cardiology/fulltext/2021/05000/racial_and_ethnic_disparities_in_heart_failure_.12.aspx"> https://journals.lww.com/co-cardiology/fulltext/2021/05000/racial_and_ethnic_disparities_in_heart_failure_.12.aspx</a></span></p> <p class="p1"><span class="s1"><a href= "https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14986">https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14986</a></span></p> <p class="p1"> </p> <p class="p1">This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.</p>
March 3, 2025
<p class="p2">With Henrique Arfsten, Medical University of Vienna, Vienna - Austria and Alexandre Mebazza, Hospital Lariboisiere, Paris - France. </p> <p class="p2">In this episode of HFA CardioTalk, Henrike Arfsten and<span class="Apple-converted-space"> </span> Alexandre Mebazaa discuss the importance of rapid initiation and titration of guideline-directed medical heart failure therapy.</p> <p class="p2">A focus will be on data from the STRONG-HF trial, which demonstrated safety and efficacy of rapid up-titration following an acute heart failure event. The trial was even stopped early as the benefits of the intensive treatment strategy were overwhelming. Moreover, specific questions are raised, such as the right time to start therapy and how to deal with possible side effects.</p> <p class="p1"><span class="s1"><a href= "https://pubmed.ncbi.nlm.nih.gov/36356631/">Mebazaa A, et al. Lancet 2022 Dec 3;400(10367):1938-52</a></span></p> <p class="p1"><a href= "https://pubmed.ncbi.nlm.nih.gov/39037564/">Biegus J, et al. Heart Fail Rev 2024 Sep;29(5):1065-1077</a></p> <p class="p1"><a href= "https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2333?msockid=19db9c90bbb1698018e08907ba056893"> McDonagh TA, et al. Eur J Heart Fail 2022 Jan;24(1):4-131</a></p> <p class="p1"><a href= "https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3024?msockid=19db9c90bbb1698018e08907ba056893"> McDonagh TA, et al. Eur J Heart Fail 2024 Jan;26(1):5-17</a></p> <p class="p1">This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.</p>
American College of Cardiology
Medscape
European Society of Cardiology
American College of Cardiology
European Society of Cardiology
CardioNerds
BMJ Group
NEJM Group
Greg Hundley, MD and Peder Myhre, MD, PhD
Mayo Clinic
Oxford University Press
Heart Failure Society of America
Mayo Clinic
American College of Cardiology
Peter Attia, MD
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.